CD166(pos) subpopulation from differentiated human ES and iPS cells support repair of acute lung injury

Previous efforts to derive lung progenitor cells from human embryonic stem (hES) cells using embryoid body formation or stromal feeder cocultures had been limited by low efficiencies. Here, we report a step-wise differentiation method to drive both hES and induced pluripotent stem (iPS) cells toward...

Full description

Saved in:
Bibliographic Details
Published inMolecular therapy Vol. 20; no. 12; pp. 2335 - 2346
Main Authors Soh, Boon Seng, Zheng, Dahai, Li Yeo, Julie Su, Yang, Henry He, Ng, Shi Yan, Wong, Lan Hiong, Zhang, Wencai, Li, Pin, Nichane, Massimo, Asmat, Atasha, Wong, Poo Sing, Wong, Peng Cheang, Su, Lin Lin, Mantalaris, Sakis A, Lu, Jia, Xian, Wa, McKeon, Frank, Chen, Jianzhu, Lim, Elaine Hsuen, Lim, Bing
Format Journal Article
LanguageEnglish
Published United States 01.12.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Previous efforts to derive lung progenitor cells from human embryonic stem (hES) cells using embryoid body formation or stromal feeder cocultures had been limited by low efficiencies. Here, we report a step-wise differentiation method to drive both hES and induced pluripotent stem (iPS) cells toward the lung lineage. Our data demonstrated a 30% efficiency in generating lung epithelial cells (LECs) that expresses various distal lung markers. Further enrichment of lung progenitor cells using a stem cell marker, CD166 before transplantation into bleomycin-injured NOD/SCID mice resulted in enhanced survivability of mice and improved lung pulmonary functions. Immunohistochemistry of lung sections from surviving mice further confirmed the specific engraftment of transplanted cells in the damaged lung. These cells were shown to express surfactant protein C, a specific marker for distal lung progenitor in the alveoli. Our study has therefore demonstrated the proof-of-concept of using iPS cells for the repair of acute lung injury, demonstrating the potential usefulness of using patient's own iPS cells to prevent immune rejection which arise from allogenic transplantation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1525-0024
DOI:10.1038/mt.2012.182